Mird237 New Link

The next steps involve rigorous multicenter trials, regulatory refinement, and the cultivation of a new generation of clinicians fluent in AI‑augmented dosimetry. With these foundations in place, MIRD237 can truly become the “new” gold standard for internal radiation dose assessment.

The MIRD system—developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)—has been the gold standard for calculating absorbed doses in targeted radionuclide therapy (TRT). Drugs like (for neuroendocrine tumors) and Pluvicto (for prostate cancer) rely on MIRD-based dosimetry to ensure that radioactive isotopes kill cancer cells without obliterating bone marrow or kidneys. mird237 new

Development of more sophisticated dosimetry models, including those incorporating motion and variable organ sizes. mird237 new

The MIRD 237 guidelines have several clinical implications: mird237 new